Urukingo rwa Kanseri ya RhoVac Peptide Urukingo RV001 kugirango rwemerwe nu biro bishinzwe umutungo w’ubwenge muri Kanada

Isaha yo muri Kanada 2022-01-24, RhoVac, uruganda rukora imiti rwibanze ku gukingira ikibyimba, yatangaje ko gusaba ipatanti (No 2710061) urukingo rwa kanseri peptide RV001 bizemerwa n’ibiro bishinzwe umutungo bwite mu by'ubwenge muri Kanada (CIPO).Mbere, isosiyete yabonye patenti zijyanye na RV001 muri Amerika, Uburayi n'Ubuyapani.Iyi nkunga ya patenti izatanga uburinzi bwagutse kuri RV001 kumasoko akomeye no kuzamura inzitizi za sosiyete.

Kimwe na patenti yatanzwe mbere, iyi patenti ikubiyemo urukingo rwa kanseri ya RV001 nibindi bitandukanye, ndetse no kuyikoresha mukuvura / gukumira kanseri metastatike ya RhoC.Muri byo, RhoC ni antigen ifitanye isano na kanseri (TAA) ikabije kurenza ubwoko butandukanye bwibibyimba.Bimaze gutangwa, ipatanti izarangira muri 2028-12 kandi biteganijwe ko izongerwa nyuma yo kubona icyemezo cyo kurinda inyongera (CSP).

01 Onilcamotide

Onilcamotide ni urukingo rwa kanseri rugizwe na peptide ikingira indwara ikomoka ku muryango wa Ras homologous C (RhoC), ushobora kwiganwa muri montanide ya immunontant ISA-51, hamwe nibikorwa bishobora gukingira no kurwanya antitumor.Ubuyobozi butandukanye bwa Onilcamotide butera ubudahangarwa bw'umubiri kwakira lymphocyte (CTL) itwenza na cytotoxic T ya selile yibibyimba bya RhoC, bityo ikabuza ingirabuzimafatizo.

2020-11, RV001 yahawe Fast Track na FDA.

02 Ibigeragezo

Muri 2018, hemejwe igeragezwa ry’icyiciro cya I / IIa cya Onilcamotide yo kuvura kanseri ya prostate, kandi abarwayi 21 bose hamwe.Ibisubizo byerekanaga ko Onilcamotide yari ifite umutekano kandi yihanganirwa.Byongeye kandi, abarwayi bagize ibisubizo bikomeye kandi biramba nyuma yo kuvurwa.Mu 2021, ubushakashatsi bwakorewe kuri 19 muri aya masomo, nyuma yimyaka itatu nyuma yo kuvurwa na RhoVac, bwerekanye ko ayo masomo atigeze akora metastase cyangwa ngo yongere kuvurwa kandi nta terambere ryihariye rya antigen (PSA)..Muri ibyo, amasomo 16 nta PSA yamenyekanye, naho amasomo 3 yari afite iterambere rya PSA.PSA ni poroteyine ikorwa na glande ya prostate kandi ikoreshwa mugukurikirana iterambere rya kanseri izwi.

Muri 2019, RV001 Phase IIb ivura BraVac (randomized, double-blind, igenzurwa na placebo) yatangijwe kugirango isuzume imikorere yayo mukurinda cyangwa kugabanya iterambere rya kanseri ya prostate nyuma yo kubagwa / imirasire.Igeragezwa rya kliniki ya IIb ni ubushakashatsi mpuzamahanga, bwibanze ku gushaka abantu mu bihugu 6 by’Uburayi (Danemarke, Finlande, Suwede, Ububiligi, Ubudage, n'Ubwongereza) na Amerika.Ikigeragezo cyarangije kwinjiza abarwayi muri 2021-09, hamwe n’amasomo agera kuri 175 yiyandikishije, akazarangira muri 2022H1.Byongeye kandi, RhoVac irateganya gukora ubushakashatsi bwibanze bugamije gutanga ibimenyetso byerekana kwaguka kwa RV001 mubyerekana.

Byongeye kandi, komite ishinzwe umutekano yanakoze isuzuma ry’agateganyo ry’umutekano RV001 mu 2021-07, kandi nta bintu bibi bitunguranye byabonetse, ibyo bikaba byari bihuye n’ibisubizo by’ubuvuzi byabanjirije icyiciro cya I / II.